Kaleido Biosciences, Inc.
Kaleido Biosciences, Inc. (KLDO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
kldo · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.00
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.00 | ↑ 0.00% |
1-day model range: $0–$0. Peak: $0 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · KLDO · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2022-04-04 | Chardan Capital | Downgrade ↓ | Buy→Neutral |
| 2022-01-31 | Chardan Capital | Maintains | Buy→Buy |
| 2021-11-12 | Chardan Capital | Maintains | Buy→Buy |
| 2021-11-03 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2021-10-19 | Morgan Stanley | Downgrade ↓ | Equal Weight→Underweight |
| 2021-03-08 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2021-02-09 | Piper Sandler | Maintains | Overweight→Overweight |
| 2021-01-19 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2020-12-23 | JMP Securities | Maintains | Outperform→Outperform |
| 2020-08-10 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
Wall Street analysts have recently issued updated ratings on Kaleido Biosciences, Inc. (KLDO) stock. Of the recent 17 rating actions, 0 were upgrades and 3 were downgrades. 7 analysts currently cover KLDO.
Analyst Recommendation Trends
KLDO analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$2M
↓ 94.4% YoY
Revenue Next Year
$1M
↓ 40.1% YoY
EPS This Year
$-2.26
EPS Next Year
$-1.16
↓ 48.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast KLDO EPS of $-2.26 for the current fiscal year, based on estimates from 1 analysts. The KLDO revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The KLDO stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus KLDO price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The KLDO short-term stock prediction for tomorrow is $0.00 (+0.00%).
Kaleido Biosciences, Inc. trades on OTC under the ticker KLDO. The KLDO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 57% of covering analysts.
Frequently asked questions
KLDO forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month KLDO price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.